Aziyo Biologics Inc. (AZYO): Price and Financial Metrics
GET POWR RATINGS... FREE!
AZYO Stock Price Chart Interactive Chart >
AZYO Price/Volume Stats
| Current price | $10.59 | 52-week high | $18.20 |
| Prev. close | $11.22 | 52-week low | $9.31 |
| Day low | $10.38 | Volume | 27,400 |
| Day high | $10.89 | Avg. volume | 20,529 |
| 50-day MA | $11.86 | Dividend yield | N/A |
| 200-day MA | $0.00 | Market Cap | 108.31M |
Aziyo Biologics Inc. (AZYO) Company Bio
Aziyo Biologics, Inc. operates as a biotechnology company which focuses on regenerative medicine in areas such as cardiology, orthopedics and other medical specialties. It offers cardiac device envelope, vascular surgery, cardiothoracic repair, orthopedics and spine, sports medicine, dermal, and wound care. The company was founded on August 6, 2015 and is headquartered in Silver Spring, MD.
Latest AZYO News From Around the Web
Below are the latest news stories about Aziyo Biologics Inc that investors may wish to consider to help them evaluate AZYO as an investment opportunity.
Are Insiders Buying Aziyo Biologics, Inc. (NASDAQ:AZYO) Stock?We often see insiders buying up shares in companies that perform well over the long term. On the other hand, we'd be... |
Aziyo Biologics Comments on June 2nd Voluntary Recall of One Lot of its FiberCel Fiber Viable Bone MatrixAziyo Biologics, Inc. (Nasdaq: AZYO) on June 2, 2021 issued a voluntary recall pertaining to a single donor lot of its FiberCel Fiber Viable Bone Matrix, a bone repair product made from human tissue that is used in various orthopedic and spinal procedures. |
Aziyo Biologics (AZYO) Investor Presentation - SlideshowThe following slide deck was published by Aziyo Biologics, Inc. in conjunction with this event.... |
Aziyo Biologics, Inc. (NASDAQ:AZYO) CEO Ronald K. Lloyd Purchases 8,565 Shares of StockAziyo Biologics, Inc. (NASDAQ:AZYO) CEO Ronald K. Lloyd bought 8,565 shares of the businesss stock in a transaction dated Friday, May 7th. The stock was purchased at an average price of $11.75 per share, with a total value of $100,638.75. Following the purchase, the chief executive officer now directly owns 21,784 shares of the companys [] |
Aziyo Biologics, Inc. Forecasted to Earn FY2021 Earnings of ($2.13) Per Share (NASDAQ:AZYO)Aziyo Biologics, Inc. (NASDAQ:AZYO) Cantor Fitzgerald cut their FY2021 earnings per share estimates for Aziyo Biologics in a report issued on Thursday, May 6th. Cantor Fitzgerald analyst B. Folkes now anticipates that the company will earn ($2.13) per share for the year, down from their previous forecast of ($2.01). Cantor Fitzgerald also issued estimates [] |
AZYO Price Returns
| 1-mo | -7.91% |
| 3-mo | -19.04% |
| 6-mo | -21.32% |
| 1-year | N/A |
| 3-year | N/A |
| 5-year | N/A |
| YTD | -22.30% |
| 2020 | N/A |
| 2019 | N/A |
| 2018 | N/A |
| 2017 | N/A |
| 2016 | N/A |
Loading social stream, please wait...